Champions Oncology, Inc.
CSBR · Price history
Price at last available close
$4.92
−$0.01 (-0.20%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Champions Oncology, Inc.
Primary reporting period: 2026-04-30 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle.
How they make money
Champions Oncology operates as a contract research organization (CRO) providing end-to-end oncology research and development solutions. The company generates revenue by offering biopharmaceutical clients access to proprietary patient-derived xenograft (PDX) models, bioanalytical platforms, and data analytics to support preclinical and clinical drug discovery programs.
Products & services
The company provides preclinical and clinical oncology research services, including PDX models, ex vivo and in vivo testing platforms, and molecular multi-omic data analysis for drug development.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Clinical Network — A network of clinical sites that provide access to patients diagnosed with prioritized tumor subtypes for research purposes.Source
Strengths
Risks
- Intense competition based on scientific and technological forcesSource
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-07-31.
Total debt increased 90.8% versus the same quarter last year.
Compare the added borrowing with available cash, cash generation and maturities. A percentage increase from a small starting balance can look large without measuring the full debt burden.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
38
Poor
Financial Strength
57
Business Quality / Moat
65
Management
0
Growth Quality
22
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
29
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
42/100
Building Historical Record
Model Score 42/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CSBR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CSBR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can CSBR fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is CSBR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for CSBR to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CSBR's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
29
Market Cap
$68.5M
P/E Ratio
-63.3
EPS
$-0.08
52-Week High
$8.31
52-Week Low
$4.59
Beta
0.40
Analyst Target
$12.00
Shares Outstanding
13.8M
Total Revenue
$60.7M
Total Debt
$11.0M
Dividend
No current dividend
Liquidation Value / Share
$0.32
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on CSBR.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Large collection of clinically relevant patient-derived models.
- +Proprietary in vivo and ex vivo platforms.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Intense competition based on scientific and technological forces.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
25
Sep 17, 2026
Change
Unchanged
Current Score
25
Oct 1, 2026
Category Changes
CSBR score was unchanged.
Projected Score
Projected Score
20
Projected Change
-4.4 points
Preliminary comparable-period financial changes suggest decline of approximately 4.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$4.92
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.7M | $59.4M | $56.9M | $50.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $30.8M | $30.9M | $28.4M | $29.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $29.9M | $28.5M | $28.6M | $20.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $9.3M | $9.1M | $6.8M | $9.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $21.8M | $20.5M | $16.9M | $18.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $31.0M | $29.7M | $23.7M | $27.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $447K | $448K | $6.3M | -$5.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$1.0M | -$1.1M | $4.8M | -$6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$892K | -$929K | $4.6M | -$7.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $243K | $246K | -$75K | -$32K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$1.1M | -$1.2M | $4.7M | -$7.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.08 | $-0.08 | $0.34 | $-0.54 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 13.90M | 13.83M | 13.66M | 13.55M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 13.90M | 13.83M | 14.27M | 13.55M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$15.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.03
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+90.8%
Cash Change
-57.8%
Margin Change
+0.5 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, net income margin. Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 8.8%. EPS declined 3.2%. Cash declined 57.8%. Total debt increased 90.8%. Net income margin improved by 0.5 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript
Champions Oncology Q1 Earnings Call Highlights
Champions Oncology Reports Revenue of $15.2 Million
Rumor Mill · CSBR
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial